Telomir Pharmaceuticals, Inc. TELO
Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) is an oncology drug developer. Its lead program, Telomir-Zn, is in Phase 1 for advanced or metastatic triple-negative breast cancer (TNBC). Its next catalyst on record is Telomir-Zn: Phase 1/2 clinical trial commencement in advanced or metastatic TNBC (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Telomir-Zn — Phase 1/2 clinical trial commencement in advanced or metastatic TNBC (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Telomir-Zn | advanced or metastatic triple-negative breast cancer | small molecule | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.